Copyright
©The Author(s) 2020.
World J Gastrointest Endosc. Sep 16, 2020; 12(9): 276-284
Published online Sep 16, 2020. doi: 10.4253/wjge.v12.i9.276
Published online Sep 16, 2020. doi: 10.4253/wjge.v12.i9.276
Case | Sex | Age (yr), number of diagnosed lesions | Age (yr), number of diagnosed lesions |
1 | Female | 79, 2 | 84, 1 |
2 | Male | 84, 2 | 87, 1 |
3 | Female | 71, 2 | |
4 | Male | 74, 1 | 77, 2 |
5 | Male | 71, 2 | |
6 | Male | 81, 3 | |
7 | Male | 63, 2 |
Characteristics | Total (n = 45) | Single (n = 38) | Multiple (n = 7) | P value |
Mean age (range), yr | 67.0 (43-86) | 65.6 (43-86) | 74.7 (63-84) | 0.039a |
Sex, n (%) | 0.61 | |||
Female | 17 (37.7) | 15 (39.4) | 2 (28.5) | |
Male | 28 (62.2) | 23 (60.5) | 5 (71.4) | |
Kyoto score, average | 4.02 | 3.81 | 5.14 | 0.016a |
Atrophic gastritis, score, n (%) | 1.71 | 1.65 | 2.00 | 0.77 |
None, 0 | 1 (2.22) | 1 (2.63) | 0 | |
C-1, 0 | 0 | 0 | 0 | |
C-2, 1 | 7 (15.5) | 7 (18.4) | 0 | |
C-3, 1 | 4 (8.88) | 4 (10.5) | 0 | |
O-1, 2 | 7 (15.5) | 6 (15.7) | 1 (14.2) | |
O-2, 2 | 7 (15.5) | 6 (15.7) | 1 (14.) | |
O-3, 2 | 19 (42.2) | 14 (36.8) | 5 (71.4) | |
Intestinal metaplasia, score, n (%) | 1.28 | 1.15 | 2.00 | 0.048a |
None, 0 | 12 (26.6) | 12 (31.5) | 0 | |
Antrum, 1 | 8 (17.7) | 8 (21.0) | 0 | |
Corpus, 2 | 25 (55.5) | 18 (47.3) | 7 (100) | |
Enlarged folds, score, n (%) | 0.06 | 0.07 | 0 | 0.44 |
None, 0 | 42 (93.3) | 35 (92.1) | 7 (100) | |
Present, 1 | 3 (6.66) | 3 (7.89) | 0 | |
Nodularity, score, n (%) | 0 | 0 | 0 | 1.00 |
None, 0 | 45 (100) | 38 (100) | 7 (100) | |
Present, 1 | 0 | 0 | 0 | |
Diffuse redness, score, n (%) | 0.95 | 0.92 | 1.14 | 0.65 |
None, 0 | 3 (6.66) | 3 (7.89) | 0 | |
With RAC, 1 | 41 (91.1) | 35 (92.1) | 6 (85.7) | |
Without RAC, 2 | 1 (2.22) | 0 | 1 (14.2) | |
Map like redness, yes | 27 (58.6) | 22 (56.4) | 5 (71.4) | 0.68 |
Mean size (range), mm | 14.8 (1.0-120) | 15.5 (1-120) | 11.1 (1.0-35) | 0.46 |
Pathology, n (%) | ||||
Intestinal type | 42 (93.3) | 35 (92.1) | 7 (100) | 0.44 |
Diffuse type | 3 (6.66) | 3 (7.89) | 0 | |
Stage, n (%) | 0.98 | |||
I | 43 (95.5) | 36 (94.7) | 7 (100) | |
II | 1 (2.22) | 1 (2.63) | 0 | |
III | 1 (2.22) | 1 (2.63) | 0 | |
IV | 0 | 0 | 0 | |
Treatment for gastric cancer, n (%) | ||||
Endoscopy | 43 (95.5) | 36 (94.7) | 7 (100) | 0.54 |
Surgery | 2 (4.44) | 2 (5.26) | 0 | |
Chemotherapy | 0 | 0 | 0 | |
Best supportive care | 0 | 0 | 0 |
- Citation: Sakitani K, Nishizawa T, Toyoshima A, Yoshida S, Matsuno T, Yamada T, Irokawa M, Takahashi Y, Nakai Y, Toyoshima O, Koike K. Kyoto classification in patients who developed multiple gastric carcinomas after Helicobacter pylori eradication. World J Gastrointest Endosc 2020; 12(9): 276-284
- URL: https://www.wjgnet.com/1948-5190/full/v12/i9/276.htm
- DOI: https://dx.doi.org/10.4253/wjge.v12.i9.276